Unit Biocon Biologics received European Commission-granted marketing authorisation in the EU for YESAFILI, a biosimilar of Aflibercept. Aflibercept had EU brand sales of approximately $1.8 billion for the 12 months ending Dec. 31, 2022, according to IQVIA.
